Evidence map›Paper›PMID 25172177›Full record

ArticleMicrovascular research2014

Cleavage and reduced CD36 ectodomain density on heart and spleen macrophages in the spontaneously hypertensive rat.

Marco H Santamaria, Angela Y Chen, Jason Chow, Diana C Muñoz, Geert W Schmid-Schönbein

Abstract read
In one paragraph

Article in Microvascular research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. IGF-1 receptor cleavage in hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2018
    Article
  7. Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marco H SantamariaDepartment of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: msantamariaaviles@gmail.com.
Angela Y ChenDepartment of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: vistacove2009@gmail.com.
Jason ChowDepartment of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: jcchow09@gmail.com.
Diana C MuñozDepartment of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: dianamunoz07@yahoo.com.
Geert W Schmid-SchönbeinDepartment of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: gwss@bioeng.ucsd.edu.
University of California, San Diego · USLa Jolla Bioengineering Institute · US

Funding

STRUCTURE/FUNCTION OF THE MICROCIRCULATIOMR01HL010881 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHMID-SCHOENBEIN, GEERT W. · 1985 to 2011
$3.1M
NHLBI NIH HHS HL-10881NHLBI NIH HHS R01 HL010881
6 · The paper itself

Abstract

Metabolic disease is accompanied by a range of cellular defects ("comorbidities") whose origin is uncertain. To investigate this pathophysiological phenomenon we used the Spontaneously Hypertensive Rat (SHR), which besides an elevated arterial blood pressure also has many other comorbidities, including a defective glucose and lipid metabolism. We have shown that this model of metabolic disease has elevated plasma matrix metalloproteinase (MMP) activity, which cleaves the extracellular domain of membrane receptors. We hypothesize here that the increased MMP activity also leads to abnormal cleavage of the scavenger receptor and fatty acid transporter CD36. To test this idea, chronic pharmaceutical MMP inhibition (CGS27023A) of the SHR and its normotensive control, the Wistar Kyoto Rat (WKY), was used to determine if inhibition of MMP activity serves to maintain CD36 receptor density and function. Surface density of CD36 on macrophages from the heart, spleen, and liver was determined in WKY, SHR, CGS-treated WKY (CGS WKY), and CGS-treated SHR (CGS SHR) by immunohistochemistry with an antibody against the CD36 ectodomain. The extracellular CD36 density was lower in SHR heart and spleen macrophages compared to that in the WKY. MMP inhibition by CGS served to restore the reduced CD36 density on SHR cardiac and splanchnic macrophages to levels of the WKY. To examine CD36 function, culture assays with murine macrophages (RAW 264.7) after incubation in fresh WKY or SHR plasma were used to test for adhesion of light-weight donor red blood cell (RBC) by CD36. This form of RBC adhesion to macrophages was reduced after incubation in SHR compared WKY plasma. Analysis of the supernatant macrophage media by Western blot shows a higher level of CD36 extracellular protein fragments following exposure to SHR plasma compared to WKY. MMP inhibition in the SHR plasma compared to untreated plasma, served to increase the RBC adhesion to macrophages and decrease the number of receptor fragments in the macrophage media. In conclusion, these studies bring to light that plasma in the SHR model of metabolic disease has an unchecked MMP degrading activity which causes cleavage of a variety of membrane receptors, including CD36, which attenuates several cellular functions typical for the metabolic disease, including RBC adhesion to the scavenger receptor CD36. In addition to other cell dysfunctions chronic MMP inhibition restores CD36 in the SHR.

Indexed as

AnimalsArterial PressureCD36 AntigensCells, CulturedDisease Models, AnimalDown-RegulationErythrocytesHypertensionMacrophagesMaleMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMyocardiumProteolysisRats, Inbred SHRRats, Inbred WKYCD36 AntigensMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesCD36MMPMMP inhibitor CGS27023ASpontaneously Hypertensive Rat (SHR)TIMP

Identifiers

PMID25172177
PMCPMC4642997
OpenAlexW2000144653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.